欢迎光临源叶生物,登录 | 注册 |
当前位置: 首页 > 小分子化合物 > 小分子抑制剂 > Trelagliptin (succinate)

商品分类

浏览历史

S80035

Trelagliptin (succinate)

MedMol 99%
  • 英文名:
  • Trelagliptin (succinate)
  • 别名:
  • Trelagliptin (succinate); SYR472 succinate; SYR 472; Trelagliptin succinate [USAN];
  • CAS号:
  • 1029877-94-8
  • 分子式:
  • C22H26FN5O6
  • 分子量:
  • 475.4702
  • 核磁/质谱:
品牌货号产品规格市场价(RMB)您的折扣价(RMB)库存(上海) 北京 武汉 南京 数量计量单位 加入购物车...
MedMol研发 S80035-5mg 99% ¥425.00元 ¥410.00元 >10 0 0 0 EA 加入购物车
MedMol研发 S80035-10mg 99% ¥765.00元 ¥580.00元 >10 0 0 0 EA 加入购物车
MedMol研发 S80035-50mg 99% ¥2975.00元 ¥980.00元 >10 0 0 0 EA 加入购物车
MedMol研发 S80035-250mg 99% ¥7650.00元 ¥1800.00元 >10 0 0 0 EA 加入购物车
大包装询价

提交您的电话号码并同意《个人信息授权与保护申明》,到货后将短信提示。
提交

产品介绍

参考文献(1篇)

质检证书(COA)

摩尔浓度计算器

相关产品

  • 提示:详情请下载说明书。
  • 产品描述: Trelagliptin (SYR-472) succinate is a potent, orally active and highly selective DPP-4 inhibitor with an IC50 of 4 nM. Trelagliptin succinate improves glycemic control in vivo and can be used for the study of type 2 diabetes mellitus (T2DM)
  • 靶点: IC50: 4 nM (DPP-4)
  • 体外研究: Dipeptidyl peptidase-4 (DPP-4) is one of the widely explored novel targets for type 2 diabetes mellitus (T2DM) strategy to preserve the endogenous glucagon like peptide (GLP)-1 activity by inhibiting the DPP-4 action. Trelagliptin exhibits potent inhibitory activity toward DPP-4 prepared from Caco-2 cells with an IC50 value of 5.4 nM. Trelagliptin also inhibits human, dog, and rat plasma DPP-4 activity with IC50 values of 4.2 nM, 6.2 nM, and 9.7 nM, respectively. Trelagliptin is highly selective for DPP-4 and displays IC50 values >100,000 nM corresponding to >10,000-fold selectivity over DPP-2, DPP-8, DPP-9, PEP and FAPα activities. Trelagliptin shows DPP4 selective about 4- and 12-fold more potent than alogliptin (HY-A0023) and sitagliptin (HY-13749), respectively
  • 体内研究: Trelagliptin (oral gavage; 7 mg/kg; single dose) shows sustained PD effect in dogs and gives >80% inhibition of DPP-4 activity even after 24h. Trelagliptin (oral gavage; 3 mg/kg; single dose; 60 min prior to oral glucose) significantly improves the glucose tolerance capacity by decreasing the AUC0−120min of 19.3% compared with the vehicle group in ob/ob mice. Trelagliptin (oral gavage; 10 mg/kg; once a week; 8 weeks) caused significant reductions in fasting blood glucose (FBG) levels, and the average reduction during the entire treatment period is 16.8% compared to the control.It also increases insulin level and raised it by 1.7-fold in AUC0−120min in ob/ob mice. Animal Model: ICR ob/ob mice Dosage: 10 mg/kg Administration: Oral gavage; 10 mg/kg; once a week; 8 weeks Result: Exerted chronic antidiabetic effects on type 2 diabetic db/db Mice.
  • 参考文献:
    1. Bhumika D Patel, et al. Recent approaches to medicinal chemistry and therapeutic potential of dipeptidyl peptidase-4 (DPP-4) inhibitors. Eur J Med Chem. 2014 Mar 3;74:574-605. 2. Charles E Grimshaw, et al. Trelagliptin (SYR-472, Zafatek), Novel Once-Weekly Treatment for Type 2 Diabetes, Inhibits Dipeptidyl Peptidase-4 (DPP-4) via a Non-Covalent Mechanism. PLoS One. 2016 Jun 21;11(6):e0157509. 3. Shiliang Li, et al. Discovery of a Natural-Product-Derived Preclinical Candidate for Once-Weekly Treatment of Type 2 Diabetes. J Med Chem. 2019 Mar 14;62(5):2348-2361.
  • 溶解性: Soluble  in  DMSO、H2O
  • 保存条件: -20℃
  • 配置溶液浓度参考:
    1mg 5mg 10mg
    1 mM 2.103 ml 10.516 ml 21.032 ml
    5 mM 0.421 ml 2.103 ml 4.206 ml
    10 mM 0.21 ml 1.052 ml 2.103 ml
    50 mM 0.042 ml 0.21 ml 0.421 ml
  • 注意:部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。
输入产品批号:

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:


质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)


  • =
    *
    *


源叶所有产品仅用作科学研究,销售产品行为均适用于我司网上所列通用销售条款。